Ligand Pharma (LGND) Posts Q3 Loss of 3c, Tops by 1c; Guides
More News related to LGND
- Ligand Pharma (LGND) Reports Data on SARM
- Ligand Presents New Preclinical Data on its Lead SARM Molecule LGD-4033 at the Gerontological Society of America Annual Meeting
- Ligand Pharma (LGND) Receives $2M in Milestone Payments from N.V. Organon
- Ligand Earns $2 Million in Milestone Payments from Merck & Co., Inc.
- Morning Movers 11/06: ACLS, CVM, ZIOP, LPSN, CABL, ZGEN Higher; NHWK, GOK, CROX, CVI, RAIL, CSTR Lower
More News related to Earnings
- Highlights From DE's Q4 Conference Call: Production Will Pick Up in 2010, But Overall Conditions to Remain Fairly Restrained
- pSivida (PSDV) Files $41.99M Mixed Securities Shelf
- HF Financial (HFFC) Closes $23M Common Offering
- Basic Energy Services (BAS) Closes $225M Senior Note Exchange Offer
- Microsoft (MSFT) and eBay (EBAY) Team Up to Offer Deals Through IE8 Web Slice
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) reports Q3 loss of $0.03, 1 cents better than the analyst estimate of ($0.04). Revenue for the quarter was $7.9 million, which compares to the estimate of $7.08 million.
Sees FY09 sales $33 - $34 million, versus $34.30 million consensus.
Related Categories
EarningsGuidance
Stocks Mentioned
-0.09Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
